RAMM Pharma Corp. Announces Corporate Update
RAMM Pharma Corp. Announces Corporate Update
TORONTO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- On September 5th 2023, RAMM Pharma Corp. (including its wholly owned subsidiaries, the "Company" or "RAMM") (CSE: RAMM), announced its intention to complete a non-brokered private placement of up to 20,000,000 units (the "Units") of the Company at a price of $0.05 per Unit for total gross proceeds of up to $1,000,000 (the "Offering"). Each Unit would have been comprised of one common share in the capital of the Company (each, a "Common Share"), and one Common Share purchase warrant (each a "Warrant"), with each Warrant entitling the holder thereof to acquire one Common Share at a price of $0.05 for a period of 36 months following the closing date of the Offering. The proceeds from the Offering were expected to be used for working capital and general corporate purposes. The Offering was expected to close on or about September 26, 2023.
多倫多，9月2023年9月12日(環球通訊社)--9月5日這是2023年，RAMM Pharma Corp.(包括其全資子公司公司“或”Ramm“)(CSE：Ramm)，宣佈有意完成最多20,000,000個單位的非經紀私募。單位“)，每單位作價0.05元，總收益不超過1,000,000元(”供奉)。每個單位將由公司股本中的一股普通股組成(每股，一股普通股)及一份普通股認購權證(每份均為搜查令“)，每份認股權證持有人有權在發售截止日期後36個月內，以0.05美元的價格收購一股普通股。發售所得款項預計將用於營運資金和一般企業用途。發售預計於2023年9月26日左右結束。
Ramm also announced its intention to commence a normal course issuer bid (the "NCIB"), under which it could have purchased up to 5% of the current number of issued and outstanding Common Shares. The NCIB would have commenced on or about September 5, 2023 and expired on the 12-month anniversary of the effective date of the NCIB.
RAMM還宣佈，它打算開始正常的發行人報價(“NCIB”)，根據該報價，它可以購買最多5%的現有已發行和已發行普通股。NCIB將於2023年9月5日左右開始生效，並在NCIB生效日期的12個月週年紀念日到期。
Further reference to the proposed non-brokered private placement and the NCIB can be found on the Company's announcement released on September 5th 2023.
The Company, after an exchange of correspondence with the CSE, has decided not to proceed with the contemplated non-brokered private placement in compliance with the CSE's view and assessment that "the Issuer has nearly $6 million in cash with no apparent immediate need for the private placement". The Company will re submit its intention to commence a NCIB.
有關建議的非經紀私募及NCIB的進一步資料，請參閱本公司於9月5日發佈的公告這是2023年。
本公司在與聯交所交換函件後，根據聯交所的意見及評估，決定不進行擬進行的非經紀私募。“發行人有近600萬美元現金，顯然不需要私募。”。本公司將重新提交其開始NCIB的意向。
About RAMM Pharma Corp.
RAMM製藥公司簡介
RAMM Pharma is a leader in the field of cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other hemp-based products with a unique and diversified international production and sales platform. The Company operates an established pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved plant-derived cannabinoid pharmaceutical products that have been authorized for sale and/or compassionate use in several Latin American countries. RAMM also has a pipeline of new products, including registered hemp-based nutrition and specialized veterinary products, in various stages of approval and development, which are produced at the company's state-of-the-art, good-manufacturing-practice-certified formulation facility in Montevideo, Uruguay.
Ramm Pharma是大麻類藥物和大麻類藥物和其他大麻類產品的產品配方領域的領先者，擁有獨特和多元化的國際生產和銷售平臺。該公司在烏拉圭經營著成熟的藥品和醫療產品業務，開發了幾種經過醫學註冊和批准的植物來源大麻類藥物，這些產品已被授權在幾個拉丁美洲國家銷售和/或同情使用。RAMM還擁有一系列新產品，包括註冊的大麻營養和專業獸醫產品，處於批准和開發的不同階段，這些產品由該公司位於烏拉圭蒙特維多的最先進、良好製造實踐認證的配方工廠生產。
In Europe, RAMM's vertically integrated operations are based in Ragusa, Italy and Elbląg, Poland (60 kilometres east of Gdańsk), and include large extraction and processing facilities (in the final stages of commissioning in the case of Canapar Corp.). RAMM Pharma includes wholly owned subsidiaries Canapar Corp., HemPoland S.p.a. Z.o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.
在歐洲，RAMM的垂直整合業務位於義大利拉古薩和波蘭Elbląg(GdańSK以東60公里)，包括大型開採和加工設施(Canapar Corp.處於投產的最後階段)。Ramm Pharma公司包括全資子公司Canapar Corp.、HEM波蘭S.p.A.Z.o.O.、Medc Plast SA、Yurelan SA、Glediser SA和RAMM Pharma Holdings Corp.
Additional information about the Company is available at .
欲瞭解更多有關該公司的資訊，請訪問：。
For further information, please contact:
如需更多資訊，請聯繫：
Jimena Reyes
Executive Assistant
+598 2513 99 58
info@rammpharma.com
希門娜·雷耶斯
行政助理
+598 2513 99 58
郵箱：Info@rammpharma.com
Cautionary Note Regarding Forward-Looking Information
關於前瞻性資訊的注意事項
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, the Company's strategies and objectives, and future expansion plans.
本新聞稿包含“前瞻性資訊”和“前瞻性陳述”(統稱為“前瞻性陳述“)在適用的加拿大證券法的含義內。除有關歷史事實的陳述外，所有陳述均為前瞻性陳述，均基於截至本新聞稿發佈之日的預期、估計和預測。任何涉及關於預測、期望、信念、計劃、預測、目標、假設、未來事件或業績的討論的陳述(經常但不總是使用諸如“預期”或“不預期”、“預計”、“預期”或“不預期”、“計劃”、“預算”、“預定”、“預測”、“估計”、“相信”或“打算”或這些詞語和短語的變體，或陳述某些行動、事件或結果“可能”或“可能”、“將”，“可能”或“將”被視為發生或實現)不是歷史事實的陳述，可能是前瞻性陳述。在本新聞稿中，前瞻性陳述涉及公司的戰略和目標以及未來的擴張計劃等。
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: future growth potential of the Company; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Uruguayan, Latin American, European and international medical and recreational cannabis markets and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Uruguay or internationally; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
這些前瞻性陳述是基於作出這些陳述時公司管理層的合理假設和估計。由於前瞻性陳述涉及已知和未知的風險、不確定因素和其他因素，可能導致公司的實際結果、業績或成就與此類前瞻性陳述明示或暗示的未來結果、業績或成就大不相同，因此未來的實際結果可能大不相同。除其他外，這些因素包括：公司未來的增長潛力；總體宏觀經濟狀況的波動；證券市場的波動；對烏拉圭、拉丁美洲、歐洲和國際醫療和娛樂用大麻市場的規模和消費者習慣變化的預期；公司成功實現業務目標的能力；擴張計劃；政治和社會不確定因素；沒有足夠的保險來承保風險和危害；存在可能在烏拉圭或國際範圍內限制大麻和大麻相關產品種植、生產、分銷和銷售的法律法規；以及員工關係。儘管本新聞稿中包含的前瞻性陳述是基於公司管理層認為或當時被認為是合理假設的，但公司不能向股東保證實際結果將與這些前瞻性陳述一致，因為可能存在其他因素導致結果與預期、估計或預期的結果不一致。讀者不應過分依賴本新聞稿中包含的前瞻性陳述和資訊。除非法律要求，否則公司不承擔更新關於信念、意見、預測或其他因素的前瞻性陳述的義務。
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
任何證券交易所、證券委員會或其他監管機構均未批准或不批准本報告所載資訊。
譯文內容由第三人軟體翻譯。